Phase I
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.
Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease.
Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC).
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.
During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
The surprising disclosure was outlined in a November 2017 letter from the FDA.
After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.
PRESS RELEASES